The Most Trusted Name in Cannabis

 

Tikun Olam is the Only Cannabis Brand — in the U.S. — Backed by Medical Research.

Completed Research Studies

1. TREATMENT OF CROHN'S DISEASE WITH CANNABIS—AN OBSERVATIONAL STUDY:

The retrospective research study was conducted by interviewing patients suffering from Crohn’s disease. The study has found very positive effects on the symptoms of the disease (number of bowel movements, quality of bowel activity, blood in stool samples, pain, etc.).

Head Researcher: Dr. Timna Naftali, Gastroenterology
Hospital: Meir Medical Center, Kfar Saba, Israel
Published in: IMAJ - The Israel Medical Association Journal, 2011

2. CANNABIS INDUCES A CLINICAL RESPONSE IN PATIENTS WITH CROHN'S DISEASE: A RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY:

In the world’s first randomized, placebo-controlled, double-blinded study of its kind, Dr. Naftali and a team of researchers used Tikun Olam’s Erez strain to produce dramatic results, with 50% of Crohn’s patients achieving “complete remission” and over 90% achieving substantial improvement – with no side effects witnessed.

Head Researcher: Dr. Timna Naftali, Gastroenterology
Hospital: Meir Medical Center, Kfar Saba, Israel
Published in: Clinical Gastroenterology& Hepatology 2013

3. THE ANTI-INFLAMMATION AND ANTI-PAIN PROPERTIES OF CANNABIS EXTRACTS:

Laboratory research study that was conducted on rodents which examines the effect of extractions of the main strains developed by Tikun Olam, on inflammation and pain, in comparison with placebo and isolated CBD.

Verification of strong effectiveness of Avidekel in comparison to infection counteracting medicines Tramadol and Aspirin, as well as a strong reactive strength in comparison to the administration of pure CBD.

Head Researcher: Prof. Ruth Gallily
Hospital: Hadassah University Hospital-Ein Kerem, Jerusalem, Israel
Published in: Pharmacology & Pharmacy, 2015, 6, 75-85

4. THE EFFECTS OF CANNABIS ON APPETITE AND BLOOD INDICES OF GERIATRIC PATIENTS:

A long-term observational follow-up conducted to collect data from elderly nursing home patients that regularly use medical cannabis. The study measures parameters such as: nutritional blood work, caloric intake, weight, prescription drug usage, sepsis, trembling, spasticity, and quality of life measurements (mood, sleeping habits, etc.)

Tikun Olam has accumulated data on a unique three year (2009-2013) research of treating old age with Tikun Olam medical cannabis strains and products in Hadarim Nursing Home. The project in Hadarim nursing home in Kibbutz Na’an has finished and the results and data are helping treat the elderly in Israel, Canada and hopefully in the future the rest of the world.

Head Researcher: Dr. Moshe Geitzen, Geriatrics
Location: Hadarim Nursing Home, Kibbutz Naan

5. THE EFFECTS OF CANNABIS ON PARKINSON'S DISORDERS:

The study was a research survey through questionnaires that examined the effects of cannabis on the motor and non- motor symptoms of patients with different movement disorders (Parkinson’s disease, Parkinson-plus syndromes, dystonia, tics and Tourette syndrome and others), including quality of life and activity of daily living as well as the side effects resulting from the cannabis consumption.

76.9% of patients reported positive effect on their general condition and mood, 64% reported improvement in pain and spasticity, and 59% reported decreased tremors and improved quality of sleep.

Head Researcher: Dr. Tanya Gurevich, Movement Disorders Unit
Hospital: Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Published in Clinical Neuropharmacology: November/December 2017 - Volume 40 - Issue 6 - p 268–272

6. EPIDEMIOLOGICAL CHARACTERISTICS, SAFETY AND EFFICACY OF MEDICAL CANNABIS IN THE ELDERLY

A prospective study that included all patients above 65 years of age who received medical cannabis from January 2015 to October 2017 in a specialized medical cannabis clinic and were willing to answer the initial questionnaire. Outcomes were pain intensity, quality of life and adverse events at six months.

The mean age was 74.5 ± 7.5 years. The most common indications for cannabis treatment were pain (66.6%) and cancer (60.8%). After six months of treatment, 93.7% of the respondents reported improvement in their condition and the reported pain level was reduced, on a scale of 0–10, from a median of 8 (on a scale of 1-10) to a median of 4. After six months, 18.1% stopped using opioid analgesics or reduced their dose.

The study found that the therapeutic use of cannabis is safe and efficacious in the elderly population.

Researchers: Raphael Mechoulam, Lihi Bar-Lev Schleider, Ran Abuhasira, Victor Novack
Hospital: Soroka University Medical Center, Ben-Gurion University of the Negev and and the Hebrew University of Jerusalem
Published in European Journal of Internal Medicine: February 7, 2018

7. PROSPECTIVE ANALYSIS OF SAFETY AND EFFICACY OF MEDICAL CANNABIS IN LARGE UNSELECTED POPULATION OF PATIENTS WITH CANCER

We analyzed the data routinely collected as part of the treatment program of 2,970 cancer patients treated with medical cannabis between 2015 and 2017.

The average age was 59.5 ± 16.3 years, 54.6% women and 26.7% of the patients reported previous experience with cannabis. The most frequent types of cancer were: breast (20.7%), lung (13.6%), pancreatic (8.1%) and colorectal (7.9%) with 51.2% being at stage
4. The main symptoms requiring therapy were sleep problems (78.4%), pain (77.7%, median intensity 8/10), weakness (72.7%), nausea (64.6%) and lack of appetite (48.9%). After six months of follow up, 902 patients (24.9%) died and 682 (18.8%) stopped the treatment. Of the remaining, 1211 (60.6%) responded; 95.9% reported an improvement in their condition, 45 patients (3.7%) reported no change and four patients (0.3%) reported deterioration in their medical condition.

Cannabis as a palliative treatment for cancer patients seems to be well-tolerated, effective and a safe option to help patients cope with the malignancy related symptoms.

Researchers: Raphael Mechoulam, Lihi Bar-Lev Schleider, Violeta Lederman, Victor Novack, Mario Hilou, Ori Lencovsky, Oded Betzalel, Liat Shbiro
Published in European Journal of Internal Medicine: February 26, 2018

Pediatric Studies in Progress

1. EFFECTS OF AVIDEKEL ON DYSTONIA AND SPASTICITY OF CEREBRAL PALSY PEDIATRIC PATIENTS:

Clinical random trial examined the effects of Avidekel oil on dystonia and spasticity in children who suffer from CP or genetic impairment.

Results have shown significant improvement in spasticity and dystonia, sleep difficulties, pain severity, and quality of life. Adverse effect included worsening of seizures in two patients; behavioral changes in two patients; somnolence in one patient.

Head Researcher: Dr. Luba Blumkin, Wolfson Hospital

2. EFFECTS OF CANNABIS ON CHILDREN DISGNOSED WITH ASD (Autistic spectrum disorder)

Retrospective cohort study of 53 patients. Study product: Avidekel oil 1:20 and Erez oil 3%.

The patients showed 75% improvement in ASD comorbidities symptoms.

Researcher: Dr. Orit Stoler
Hosptal: Assaf Harofeh Medical Center

3. EFFECTS OF MEDICAL CANNABIS ON CHILDREN AND ADOLESCENTS WITH EPILEPSY:

Retrospective cohort study of 74 patients. The purpose of the study was to describe the experience of five Israeli pediatric epilepsy clinics treating children and adolescents diagnosed as having intractable epilepsy with a regimen of medical cannabis oil, including Avidekel oil 1:20.

Results: most of the patients (66/74, 89%) reported some reduction in seizure frequency.

Chief Researcher: Dr. Michal Zadok
Medical centers: Sheba, Sourasky, Wolfson, Assaf Harofeh, MCU MOH

Clinical Studies in Progress

1. THE EFFECTS OF CANNABIS ON COLITIS:

Clinical research comparing a group of patients who will be given Erez strain cannabis cigarettes (0.5 grams per cigarette) and a group of patients who will be given placebo cigarettes (a total of two cigarettes per day) for a period of eight weeks, during which the effect of the substance on blood inflammation indices, life quality, medicine consumption, and adverse side effects etc., will be monitored.

Head Researcher: Dr. Timna Naftali, Gastroenterology
Hospital: Meir Medical Center, Kfar Saba, Israel

2. THE EFFECTS OF CANNABIS ON CROHN'S DISEASE:

Clinical research comparing a test group, receiving the Avidekel strain, and a control group (placebo), in order to examine the effect of cannabis administered with oil on the inflammatory intestinal disease. The oil contains a high concentration of CBD (200 mg) and a low concentration of THC (59 mg) and is administered twice a day.

Head Researcher: Dr. Timna Naftali, Gastroenterology
Hospital: Meir Medical Center, Kfar Saba, Israel

3. CANNABIS AND IBD DATA COLLECTION:

Large-scale, long-term data collection study on patients with a permit for medical cannabis that suffer from inflammatory bowel disease (IBD) to determine the effect of cannabis use on the symptoms and adverse side effects of the disease over a long time period. The study will look at different ingestion methods and various cannabis strains to determine their impact.

Head Researcher: Dr. Timna Naftali, Gastroenterology
Hospital: Meir Medical Center, Kfar Saba, Israel

Laboratory Research in Progress

THE EFFECTS OF CANNABIS ON IMMUNE RESPONSE:

The effect of extracts of Avidekel, Erez and Midnight on immune response in blood samples in which infection was induced.

Verification of a suppressing effect of natural cannabinoids on the release of inflammation triggering cytokines; indication of a possible inflammation preventing effect of CBD on the immune system.

Head Researcher: Dr. Yishay Sekely
Hospital: Tel Aviv Sourasky